Governance Processes and Challenges for Reservation of Antimicrobials Exclusively for Human Use and Restriction of Antimicrobial Use in Animals
The majority of antimicrobials that are produced are administered to animals, particularly food animals. While the overall impact of antimicrobial use in animals on antimicrobial resistance in humans and the environment is unclear, it undeniably has a role. Yet, some degree of antimicrobial use in animals is necessary for animal health and welfare purposes. Balancing the benefits and risks of antimicrobial use in animals is challenging because of the complexity of the problem and limitations in available data. However, a range of measures can be implemented to reduce, refine and optimize antimicrobial use in animals, with a goal of minimizing the impact on human and environmental health while maintaining necessary therapeutic use in animals. A pandemic instrument can provide the necessary foundation for the whole-of-society and whole-of government One Health approach that is required to strengthen surveillance, communication, collaboration, and action.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics - 50(2022), S2 vom: 08., Seite 55-63 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Scott Weese, J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Agriculture |
|---|
| Anmerkungen: |
Date Completed 10.03.2023 Date Revised 05.05.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1017/jme.2022.80 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35395070X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35395070X | ||
| 003 | DE-627 | ||
| 005 | 20231226061151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1017/jme.2022.80 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM35395070X | ||
| 035 | |a (NLM)36889346 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Scott Weese, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Governance Processes and Challenges for Reservation of Antimicrobials Exclusively for Human Use and Restriction of Antimicrobial Use in Animals |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.03.2023 | ||
| 500 | |a Date Revised 05.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The majority of antimicrobials that are produced are administered to animals, particularly food animals. While the overall impact of antimicrobial use in animals on antimicrobial resistance in humans and the environment is unclear, it undeniably has a role. Yet, some degree of antimicrobial use in animals is necessary for animal health and welfare purposes. Balancing the benefits and risks of antimicrobial use in animals is challenging because of the complexity of the problem and limitations in available data. However, a range of measures can be implemented to reduce, refine and optimize antimicrobial use in animals, with a goal of minimizing the impact on human and environmental health while maintaining necessary therapeutic use in animals. A pandemic instrument can provide the necessary foundation for the whole-of-society and whole-of government One Health approach that is required to strengthen surveillance, communication, collaboration, and action | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Agriculture | |
| 650 | 4 | |a Antimicrobial Resistance | |
| 650 | 4 | |a Antimicrobial Stewardship | |
| 650 | 4 | |a One Health | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 700 | 1 | |a Da Costa Junior, Guilherme Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez-Zorn, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Hardefeldt, Laura Y |e verfasserin |4 aut | |
| 700 | 1 | |a Matheu, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Moulin, Gerard |e verfasserin |4 aut | |
| 700 | 1 | |a Page, Stephen W |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Ruby |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Junxia |e verfasserin |4 aut | |
| 700 | 1 | |a Valsson, Olafur |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics |d 1993 |g 50(2022), S2 vom: 08., Seite 55-63 |w (DE-627)NLM076032787 |x 1748-720X |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2022 |g number:S2 |g day:08 |g pages:55-63 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1017/jme.2022.80 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2022 |e S2 |b 08 |h 55-63 | ||